Meridian Bioscience Company Profile (NASDAQ:VIVO)

About Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience logoMeridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:VIVO
  • CUSIP: 58958410
  • Web: www.meridianbioscience.com
Capitalization:
  • Market Cap: $596.12 million
  • Outstanding Shares: 42,203,000
Average Prices:
  • 50 Day Moving Avg: $13.83
  • 200 Day Moving Avg: $14.20
  • 52 Week Range: $10.75 - $19.85
P/E:
  • Trailing P/E Ratio: 28.40
  • Foreward P/E Ratio: 20.77
  • P/E Growth: 1.23
Sales & Book Value:
  • Annual Revenue: $198.07 million
  • Price / Sales: 3.01
  • Book Value: $3.97 per share
  • Price / Book: 3.56
Dividend:
  • Annual Dividend: $0.50
  • Dividend Yield: 3.5%
Profitability:
  • EBIDTA: $52.8 million
  • Net Margins: 0.48%
  • Return on Equity: 0.57%
  • Return on Assets: 0.39%
Debt:
  • Debt-to-Equity Ratio: 0.31%
  • Current Ratio: 6.47%
  • Quick Ratio: 4.42%
Misc:
  • Average Volume: 223,033 shs.
  • Beta: 0.86
  • Short Ratio: 15.83
 

Frequently Asked Questions for Meridian Bioscience (NASDAQ:VIVO)

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?

Meridian Bioscience declared a quarterly dividend on Thursday, July 27th. Investors of record on Monday, August 7th will be given a dividend of $0.125 per share on Thursday, August 17th. This represents a $0.50 annualized dividend and a dividend yield of 3.54%. The ex-dividend date is Thursday, August 3rd. View Meridian Bioscience's Dividend History.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its earnings results on Thursday, July, 27th. The company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. The firm earned $50.14 million during the quarter, compared to analyst estimates of $49.13 million. Meridian Bioscience had a net margin of 0.48% and a return on equity of 0.57%. Meridian Bioscience's quarterly revenue was down 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.21 earnings per share. View Meridian Bioscience's Earnings History.

When will Meridian Bioscience make its next earnings announcement?

Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Meridian Bioscience.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $0.64-0.69 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.68. The company issued revenue guidance of $193-199 million, compared to the consensus revenue estimate of $197.58 million.

Where is Meridian Bioscience's stock going? Where will Meridian Bioscience's stock price be in 2017?

4 brokerages have issued 1 year price objectives for Meridian Bioscience's shares. Their predictions range from $9.00 to $19.00. On average, they anticipate Meridian Bioscience's stock price to reach $14.33 in the next year. View Analyst Ratings for Meridian Bioscience.

Who are some of Meridian Bioscience's key competitors?

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the folowing people:

  • John A. Kraeutler, Chairman of the Board, President, Chief Executive Officer
  • Lawrence J. Baldini, Executive Vice President and President, Global Operations
  • Richard L. Eberly, Executive Vice President, President, Chief Commercial Officer
  • Melissa A. Lueke, Chief Financial Officer, Executive Vice President, Secretary
  • Marco G. Calzavara, President and Managing Director of Meridian Bioscience Europe
  • Vecheslav A. Elagin Ph.D., Executive Vice President - Research and Development
  • Susan D. Rolih, Executive Vice President - Regulatory & Quality Systems
  • David C. Phillips, Lead Independent Director
  • James M. Anderson, Independent Director
  • Dwight E. Ellingwood, Independent Director

Who owns Meridian Bioscience stock?

Meridian Bioscience's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.52%), Renaissance Technologies LLC (4.66%), Dimensional Fund Advisors LP (3.95%), State Street Corp (2.92%), New York State Common Retirement Fund (2.51%) and Prudential PLC (2.19%). Company insiders that own Meridian Bioscience stock include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.

Who sold Meridian Bioscience stock? Who is selling Meridian Bioscience stock?

Meridian Bioscience's stock was sold by a variety of institutional investors in the last quarter, including Prudential PLC, BTIM Corp., Wells Fargo & Company MN, Citadel Advisors LLC, Schroder Investment Management Group, North Star Investment Management Corp., Systematic Financial Management LP and Nine Chapters Capital Management LLC. Company insiders that have sold Meridian Bioscience stock in the last year include Richard Eberly and Vecheslav A Elagin. View Insider Buying and Selling for Meridian Bioscience.

Who bought Meridian Bioscience stock? Who is buying Meridian Bioscience stock?

Meridian Bioscience's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Intrinsic Edge Capital Management LLC, Dimensional Fund Advisors LP, Prudential Financial Inc., GSA Capital Partners LLP, OxFORD Asset Management LLP, Balter Liquid Alternatives LLC and Parametric Portfolio Associates LLC. Company insiders that have bought Meridian Bioscience stock in the last two years include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.

How do I buy Meridian Bioscience stock?

Shares of Meridian Bioscience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of Meridian Bioscience stock can currently be purchased for approximately $14.13.


MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)
Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  313
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Meridian Bioscience (NASDAQ:VIVO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings
Consensus Rating:Hold (Score: 1.75)
Consensus Price Target: $14.33 (1.47% upside)

Analysts' Ratings History for Meridian Bioscience (NASDAQ:VIVO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/3/2017Canaccord GenuityBoost Price TargetHold$13.00 -> $15.00LowView Rating Details
3/28/2017CL KingInitiated CoverageNeutral -> NeutralHighView Rating Details
1/31/2017Craig HallumDowngradeBuy -> HoldN/AView Rating Details
1/25/2017Piper Jaffray CompaniesSet Price TargetSell$9.00N/AView Rating Details
7/29/2016Hilliard LyonsDowngradeBuy -> HoldN/AView Rating Details
3/29/2016Robert W. BairdReiterated RatingHold$20.00N/AView Rating Details
1/27/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Meridian Bioscience (NASDAQ:VIVO)
Earnings by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Earnings History by Quarter for Meridian Bioscience (NASDAQ VIVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017$0.15N/AView Earnings Details
7/27/2017Q3 2017$0.16$0.16$49.13 million$50.14 millionViewN/AView Earnings Details
4/28/2017Q2 2017$0.19$0.22$51.16 million$54.13 millionViewN/AView Earnings Details
1/25/2017Q1 2017$0.20$0.15$51.15 million$46.80 millionViewN/AView Earnings Details
11/10/2016Q4 2016$0.14$0.14$47.17 million$47.00 millionViewN/AView Earnings Details
7/28/2016Q3$0.22$0.21$52.85 million$50.70 millionViewN/AView Earnings Details
4/28/2016Q2$0.24$0.24$52.10 million$51.30 millionViewN/AView Earnings Details
1/27/2016Q1$0.21$0.21$48.60 million$47.20 millionViewN/AView Earnings Details
11/5/2015Q4$0.21$0.20$45.70 million$47.10 millionViewN/AView Earnings Details
7/23/2015Q3$0.22$0.22$48.60 million$48.20 millionViewN/AView Earnings Details
4/23/2015Q115$0.24$0.24$50.50 million$51.55 millionViewN/AView Earnings Details
1/22/2015Q414$0.19$0.19$46.20 million$48.00 millionViewN/AView Earnings Details
11/6/2014Q4$0.22$0.20$48.94 million$46.70 millionViewN/AView Earnings Details
7/24/2014Q3$0.22$0.21$47.96 million$47.20 millionViewN/AView Earnings Details
4/24/2014Q214$0.27$0.24$52.18 million$50.13 millionViewN/AView Earnings Details
1/22/2014Q114$0.18$0.18$47.59 million$44.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.23$0.22$49.24 million$48.96 millionViewN/AView Earnings Details
7/25/2013Q3 2013$0.21$0.24$47.00 million$47.10 millionViewN/AView Earnings Details
4/25/2013Q2 2013$0.24$0.24$49.66 million$47.26 millionViewN/AView Earnings Details
1/23/2013Q1 2013$0.19$0.20$44.34 million$45.40 millionViewN/AView Earnings Details
11/8/2012Q412$0.19$0.21$43.22 million$43.70 millionViewN/AView Earnings Details
7/26/2012$0.22$0.21ViewN/AView Earnings Details
4/26/2012$0.21$0.23ViewN/AView Earnings Details
1/25/2012$0.19$0.17ViewN/AView Earnings Details
11/10/2011$0.19$0.18ViewN/AView Earnings Details
7/21/2011$0.21$0.17ViewN/AView Earnings Details
4/21/2011$0.20$0.20ViewN/AView Earnings Details
1/20/2011$0.19$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Meridian Bioscience (NASDAQ:VIVO)
2017 EPS Consensus Estimate: $0.81
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.17$0.17$0.17
Q2 20171$0.22$0.22$0.22
Q3 20171$0.22$0.22$0.22
Q4 20171$0.20$0.20$0.20
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Meridian Bioscience (NASDAQ:VIVO)
Most Recent Dividend:8/17/2017
Annual Dividend:$0.50
Dividend Yield:3.54%
Payout Ratio:98.04% (Trailing 12 Months of Earnings)
74.63% (Based on This Year's Estimates)
73.53% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Dividend History by Quarter for Meridian Bioscience (NASDAQ VIVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/27/2017Quarterly$0.133.55%8/3/20178/7/20178/17/2017
4/27/2017quarterly$0.133.33%5/4/20175/8/20175/18/2017
1/25/2017quarterly$0.133.91%2/2/20172/6/20172/16/2017
11/10/2016Quarterly$0.204.6%11/17/201611/21/201612/1/2016
7/28/2016quarterly$0.204.13%8/4/20168/8/20168/18/2016
4/28/2016quarterly$0.204.19%5/5/20165/9/20165/19/2016
1/27/2016quarterly$0.204.29%2/4/20162/8/20162/18/2016
11/5/2015quarterly$0.203.89%11/12/201511/16/201511/27/2015
7/23/2015quarterly$0.204.28%7/30/20158/3/20158/13/2015
4/23/2015quarterly$0.204.18%4/30/20155/4/20155/14/2015
1/22/2015quarterly$0.204.51%1/29/20152/2/20152/13/2015
11/6/2014quarterly$0.204.75%11/13/201411/17/201411/28/2014
7/24/2014quarterly$0.203.99%7/31/20148/4/20148/14/2014
4/24/2014quarterly$0.204.05%5/1/20145/5/20145/15/2014
1/22/2014quarterly$0.203.13%1/30/20142/3/20142/14/2014
11/7/2013quarterly$0.193.04%11/14/201311/18/201311/29/2013
7/25/2013quarterly$0.193.13%8/1/20138/5/20138/15/2013
4/25/2013quarterly$0.193.88%5/1/20135/4/20135/14/2013
12/4/2012quarterly$0.1912/14/201212/24/2012
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Meridian Bioscience (NASDAQ:VIVO)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 87.27%
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2017John A KraeutlerChairmanBuy7,000$13.67$95,690.00View SEC Filing  
2/2/2017Melissa LuekeCFOBuy4,000$12.59$50,360.00View SEC Filing  
1/26/2017Lawrence BaldiniEVPBuy4,000$12.70$50,800.00View SEC Filing  
12/2/2016Vecheslav A ElaginEVPSell7,883$17.30$136,375.90View SEC Filing  
11/30/2016Dwight E EllingwoodDirectorBuy1,020$17.12$17,462.40View SEC Filing  
11/16/2016Richard EberlyEVPSell4,926$17.00$83,742.00View SEC Filing  
11/4/2016John A KraeutlerChairmanBuy5,000$16.13$80,650.00View SEC Filing  
11/3/2016Lawrence BaldiniEVPBuy4,900$16.00$78,400.00View SEC Filing  
8/11/2016John McilwraithDirectorBuy1,000$19.57$19,570.00View SEC Filing  
4/29/2016Catherine SazdanoffDirectorBuy7,700$19.20$147,840.00View SEC Filing  
12/9/2015Vecheslav A ElaginEVPSell7,500$19.75$148,125.00View SEC Filing  
12/1/2015Richard EberlyEVPSell4,934$19.61$96,755.74View SEC Filing  
3/2/2015Marviette D JohnsonVPSell1,917$19.91$38,167.47View SEC Filing  
1/23/2015Dwight E EllingwoodDirectorBuy1,980$17.74$35,125.20View SEC Filing  
12/1/2014Susan RolihEVPSell11,219$16.46$184,664.74View SEC Filing  
11/21/2014Dwight E EllingwoodDirectorBuy1,000$16.08$16,080.00View SEC Filing  
11/18/2014John A KraeutlerCEOSell10,500$16.20$170,100.00View SEC Filing  
11/18/2014Melissa LuekeCFOSell6,713$16.20$108,750.60View SEC Filing  
11/11/2014David PhillipsDirectorBuy10,000$16.89$168,900.00View SEC Filing  
6/13/2014Robert J ReadyDirectorSell2,700$20.03$54,081.00View SEC Filing  
12/5/2013Vecheslav ElaginEVPSell4,141$23.74$98,307.34View SEC Filing  
11/22/2013Susan RolihEVPSell9,086$24.18$219,699.48View SEC Filing  
11/21/2013Richard EberlyEVPSell4,926$24.50$120,687.00View SEC Filing  
11/19/2013Lawrence BaldiniVPSell4,926$24.26$119,504.76View SEC Filing  
11/11/2013John KraeutlerCEOSell5,250$25.27$132,667.50View SEC Filing  
7/26/2013Lawrence BaldiniVPSell32,000$24.14$772,480.00View SEC Filing  
5/1/2013John A KraeutlerCEOBuy5,000$19.63$98,150.00View SEC Filing  
12/3/2012Lawrence BaldiniVPSell32,500$20.00$650,000.00View SEC Filing  
11/13/2012Robert J ReadyDirectorSell1,800$19.46$35,028.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Meridian Bioscience (NASDAQ:VIVO)
Latest Headlines for Meridian Bioscience (NASDAQ:VIVO)
Source:
DateHeadline
americanbankingnews.com logoMeridian Bioscience (VIVO) vs. The Competition Financial Comparison
www.americanbankingnews.com - September 24 at 6:34 AM
americanbankingnews.com logo$47.70 Million in Sales Expected for Meridian Bioscience Inc. (VIVO) This Quarter
www.americanbankingnews.com - September 22 at 1:30 AM
americanbankingnews.com logoComparing Meridian Bioscience (VIVO) and CryoLife (CRY)
www.americanbankingnews.com - September 20 at 2:22 PM
finance.yahoo.com logoMeridian Contributes to Upcoming “LEADCON 2017” – Third Annual International Conference on the Prevention of Lead and Heavy Metal Toxicity in Hyderabad, India
finance.yahoo.com - September 19 at 9:22 AM
finance.yahoo.com logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : September 14, 2017
finance.yahoo.com - September 15 at 11:01 AM
streetinsider.com logoMeridian Bioscience (VIVO) Launches TRU Block ULTRA
www.streetinsider.com - September 7 at 10:54 AM
americanbankingnews.com logoCytori Therapeutics (CYTX) & Meridian Bioscience (VIVO) Financial Analysis
www.americanbankingnews.com - September 6 at 8:26 PM
finance.yahoo.com logoMeridian Launches TRU Block® ULTRA – A Powerful Immunoassay Interference Blocker
finance.yahoo.com - September 6 at 9:53 AM
americanbankingnews.com logoMeridian Bioscience Inc. (VIVO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 5 at 4:32 AM
americanbankingnews.com logo Analysts Anticipate Meridian Bioscience Inc. (VIVO) Will Post Quarterly Sales of $47.70 Million
www.americanbankingnews.com - September 4 at 11:40 AM
americanbankingnews.com logo$0.14 EPS Expected for Meridian Bioscience Inc. (VIVO) This Quarter
www.americanbankingnews.com - September 2 at 4:20 AM
finance.yahoo.com logoETFs with exposure to Meridian Bioscience, Inc. : August 28, 2017
finance.yahoo.com - August 29 at 9:26 AM
americanbankingnews.com logoInsider Buying: Meridian Bioscience Inc. (VIVO) Chairman Acquires 7,000 Shares of Stock
www.americanbankingnews.com - August 25 at 1:28 PM
finance.yahoo.com logoMeridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q3, 2017 By the Numbers : August 21, 2017
finance.yahoo.com - August 23 at 1:32 PM
americanbankingnews.com logoZacks: Analysts Expect Meridian Bioscience Inc. (VIVO) Will Announce Quarterly Sales of $47.70 Million
www.americanbankingnews.com - August 16 at 3:42 AM
americanbankingnews.com logo Brokerages Anticipate Meridian Bioscience Inc. (VIVO) Will Announce Earnings of $0.15 Per Share
www.americanbankingnews.com - August 14 at 4:26 PM
americanbankingnews.com logoHead-To-Head Analysis: Meridian Bioscience (VIVO) and West Pharmaceutical Services (WST)
www.americanbankingnews.com - August 12 at 10:08 PM
americanbankingnews.com logoMeridian Bioscience Inc. (VIVO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 11 at 10:56 AM
zacks.com logoMeridian (VIVO) Initiates illumigene CMV Trial, Shares Shine
www.zacks.com - August 10 at 9:27 AM
finance.yahoo.com logoMeridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test
finance.yahoo.com - August 10 at 9:27 AM
finance.yahoo.com logoMeridian Bioscience Elects John Rice to the Board of Directors
finance.yahoo.com - August 9 at 8:55 AM
finance.yahoo.com logoMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : August 8, 2017
finance.yahoo.com - August 9 at 8:55 AM
finance.yahoo.com logoBioline Launches New JetSeq™ Clean Kit for Next-Generation Sequencing
finance.yahoo.com - August 3 at 8:36 AM
americanbankingnews.com logoMeridian Bioscience Inc. (VIVO) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - August 2 at 5:12 PM
americanbankingnews.com logoMeridian Bioscience Inc. Plans Quarterly Dividend of $0.13 (NASDAQ:VIVO)
www.americanbankingnews.com - July 28 at 10:43 AM
finance.yahoo.com logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : July 27, 2017
finance.yahoo.com - July 28 at 9:42 AM
finance.yahoo.com logoMeridian Bioscience meets 3Q profit forecasts
finance.yahoo.com - July 28 at 9:42 AM
americanbankingnews.com logoMeridian Bioscience Inc. (NASDAQ:VIVO) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - July 27 at 7:52 PM
americanbankingnews.com logoMeridian Bioscience Inc. (NASDAQ:VIVO) Announces Quarterly Earnings Results
www.americanbankingnews.com - July 27 at 2:17 PM
americanbankingnews.com logoMeridian Bioscience Inc. (NASDAQ:VIVO) Releases FY17 Earnings Guidance
www.americanbankingnews.com - July 27 at 10:07 AM
nasdaq.com logoMeridian Bioscience Q3 Profit Down 97%, Reiterates FY17 Outlook - Quick Facts
www.nasdaq.com - July 27 at 9:10 AM
finance.yahoo.com logoThe Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Meridian Bioscience, Inc.
finance.yahoo.com - July 27 at 9:10 AM
finance.yahoo.com logoMeridian Bioscience Reports Third Fiscal Quarter 2017 Operating Results, Including Non-Cash Goodwill Impairment Charge,Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance Excluding the Effect of Goodwill Impairment Charge
finance.yahoo.com - July 27 at 9:10 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Meridian Bioscience, Inc. - VIVO
finance.yahoo.com - July 26 at 9:48 AM
finance.yahoo.com logoMeridian Announces Wholly Foreign Owned Enterprise (WFOE) Office in Beijing, China
finance.yahoo.com - July 21 at 8:26 AM
americanbankingnews.com logoMeridian Bioscience Inc. (VIVO) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - July 17 at 11:05 AM
finance.yahoo.com logoFDA raises fresh concerns over Meridian's lead testing device
finance.yahoo.com - July 14 at 9:45 AM
finance.yahoo.com logoMeridian Bioscience Comments on Recent FDA Press Statement
finance.yahoo.com - July 14 at 9:45 AM
finance.yahoo.com logoFDA raises concerns about Meridian's plant that makes lead tests
finance.yahoo.com - July 14 at 9:45 AM
finance.yahoo.com logoVIVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Concerning Possible Securities Violations by Meridian Bioscience, Inc.
finance.yahoo.com - July 14 at 9:45 AM
finance.yahoo.com logoMERIDIAN BIOSCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Meridian Bioscience, Inc. To Contact The Firm
finance.yahoo.com - July 14 at 9:45 AM
americanbankingnews.com logoZacks Investment Research Lowers Meridian Bioscience Inc. (VIVO) to Sell
www.americanbankingnews.com - July 13 at 8:50 AM
americanbankingnews.com logoHead to Head Contrast: Hill-Rom Holdings (HRC) & Meridian Bioscience (VIVO)
www.americanbankingnews.com - July 12 at 7:47 AM
americanbankingnews.com logoBidaskClub Downgrades Meridian Bioscience Inc. (VIVO) to Hold
www.americanbankingnews.com - July 6 at 3:20 PM
americanbankingnews.com logoZacks: Analysts Expect Meridian Bioscience Inc. (VIVO) Will Announce Quarterly Sales of $49.41 Million
www.americanbankingnews.com - July 5 at 11:47 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Meridian Bioscience Inc. (NASDAQ:VIVO) Will Post Earnings of $0.16 Per Share
www.americanbankingnews.com - July 3 at 9:18 AM
americanbankingnews.com logoMeridian Bioscience Inc. (VIVO) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 2 at 4:24 PM
streetinsider.com logoMeridian Bioscience (VIVO) Publishes Clarifying Comments in Response to U.S. Senators, FDA & CDC Regarding FDA Safety Notification Request
www.streetinsider.com - July 1 at 8:50 AM
finance.yahoo.com logoMeridian Bioscience Comments on Recent FDA Matters Related to Magellan Diagnostics
finance.yahoo.com - July 1 at 8:50 AM
seekingalpha.com logoMeridian Bioscience updates on FDA inpsection of Magellan
seekingalpha.com - June 30 at 1:59 PM

Social

Chart

Meridian Bioscience (VIVO) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff